1997
DOI: 10.2214/ajr.168.5.9129412
|View full text |Cite
|
Sign up to set email alerts
|

Hepatic iron overload: diagnosis and quantification with MR imaging.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
80
1
1

Year Published

1999
1999
2015
2015

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 127 publications
(86 citation statements)
references
References 14 publications
4
80
1
1
Order By: Relevance
“…16 It has also been reported that lower iron accumulation is better demonstrated in gradient echo sequences, whereas iron overload is better visualized in spin echo sequences. [17][18][19] In our case, the hepatic iron load was estimated to be 44±20 µmol/g (normal <36 µmol/g) in T 2 sequences, which is consistent with mild degrees of iron load.…”
Section: Discussionsupporting
confidence: 74%
“…16 It has also been reported that lower iron accumulation is better demonstrated in gradient echo sequences, whereas iron overload is better visualized in spin echo sequences. [17][18][19] In our case, the hepatic iron load was estimated to be 44±20 µmol/g (normal <36 µmol/g) in T 2 sequences, which is consistent with mild degrees of iron load.…”
Section: Discussionsupporting
confidence: 74%
“…A prior study [4] found that liver T2 values correlated with hepatic iron concentration and with serum ferritin. These and other studies [12] have established that MRI is a reliable and useful noninvasive tool for quantifying hepatic iron in iron overload states.…”
Section: Discussionmentioning
confidence: 75%
“…In patients with serum ferritin (above normal value), a quantitative measurement of LIC by T2* MRI using gradient echo sequences and signal intensity ratio was performed as previously described. 10 An evaluation of HFE (C282Y) status at pre-transplant on available frozen DNA was made. Exclusion criteria were: hepatitis C or active hepatitis B, alcoholism (at least one positive response according to CAGE questionnaire), patients continuing immunosuppressive therapy or hepatotoxic drug administration, patients with clinical GVH or prior histologically documented chronic graft versus host disease or veno-occlusive disease, patients with active documented bleeding requiring blood transfusion after the one year period following transplant, patients with inflammation (sedimentation rate of more than 30 and/or C Reactive Protein more than >5 mg/L), patients who developed a neoplastic disease or relapsed during the 21 month study period.…”
Section: Design and Methodsmentioning
confidence: 99%